Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Clinical evidence

STOP-HAE

51 evidence topics · 15 sources

Objective
Location and study date
UK research ethics committee opinion
Study design
Registry design details
Eligibility criteria
Treatment
Registry interventions
Randomized treatment groups and injection volumes
Treatment groupReported value
Onvuzosiran every 6 months“ADX-324 300 mg Q6M (1.5ml)”
Onvuzosiran every 3 months“ADX-324 240 mg Q3M (1.2ml)”
Placebo, larger volume“Placebo (1.5 ml) n=15”
Placebo, smaller volume“Placebo (1.2 ml) n=15”
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed

No evidence found.

Description of analysis sets
Analysis populations

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

No results are available. The trial began in August 2025, enrollment is ongoing, and the estimated primary completion date is November 2027, with topline data expected by the end of 2027. Planned enrollment is approximately 90 participants: 30 per onvuzosiran group and 30 receiving placebo, divided into two injection volumes of 15 participants each. This sample size limits the precision of safety estimates and of any subgroup analysis. The primary endpoint compares only the 300 mg every-6-months group with placebo; the 240 mg every-3-months comparison is a secondary endpoint. The controlled period lasts 25 weeks, so participants in the every-6-months group receive one active dose and the controlled data do not cover a second 6-month dosing interval. Attacks before Day 22 are excluded from the primary analysis, so the primary endpoint does not describe protection during the first 3 weeks after the first dose. The comparator is placebo, so the trial does not provide a direct comparison with an approved long-term prophylactic agent. Eligibility is limited to adults with type I or type II HAE who have at least 1 investigator-confirmed attack in the first 4 weeks of screening or at least 2 in 8 weeks, who complete washout of long-term prophylaxis, and who are judged able to use on-demand treatment alone; HAE with normal C1 inhibitor, clinically significant renal or hepatic disease, and prior RNA- or DNA-based HAE therapy are excluded. The doses were selected from pharmacodynamic data in healthy volunteers and from the attack-free intervals of 3 participants with HAE whose phase 2a doses were lower or less frequent than the phase 3 regimens. The design is described only in the registry record, ethics summaries, and sponsor documents; no peer-reviewed protocol publication was identified.